Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR T-cells and DC vaccine in advanced malignancies
NCT01697527Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Nov 2012
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of mipetresgene autoleucel in malignant neoplasm, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Nov 2012; status: active, not recruiting.
02
Drugs
mipetresgene autoleucel
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT01697527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697527.